“`html
Genflow Biosciences (OTCQB:GENFF), Europe’s only publicly listed longevity company, has confirmed its previously announced €4 million non-dilutive grant from Belgium’s Wallonia Region. The funding will support the development of GF-1002, the company’s lead gene therapy candidate for treating Metabolic Associated Steatohepatitis (MASH).
The grant covers a three-year development program aligned with Genflow’s clinical roadmap. While initial disbursement awaits administrative procedures, the company has ensured the GF-1002 program continues without interruption or delays to planned research and development activities.
Genflow Biosciences (OTCQB:GENFF), l’unica società europea quotata in borsa nel settore della longevità, ha confermato il suo precedente annuncio riguardante una contributo non diluitivo di 4 milioni di euro da parte della Regione Vallonia in Belgio. Questo finanziamento sosterrà lo sviluppo di GF-1002, il principale candidato della società per la terapia genica destinata al trattamento della Steatoepatite Metabolica Associata (MASH).
Il contributo copre un programma di sviluppo triennale in linea con la tabella di marcia clinica di Genflow. Sebbene il primo erogamento sia in attesa delle procedure amministrative, l’azienda ha garantito che il programma GF-1002 proseguirà senza interruzioni né ritardi nelle attività di ricerca e sviluppo pianificate.
Genflow Biosciences (OTCQB:GENFF), la única empresa europea de longevidad que cotiza en bolsa, ha confirmado su subvención no dilutiva de 4 millones de euros previamente anunciada por la Región de Valonia en Bélgica. Esta financiación apoyará el desarrollo de GF-1002, el principal candidato a terapia génica de la compañía para tratar la Esteatohepatitis Metabólica Asociada (MASH).
La subvención cubre un programa de desarrollo de tres años alineado con la hoja de ruta clínica de Genflow. Aunque el desembolso inicial está pendiente de procedimientos administrativos, la compañía ha asegurado que el programa GF-1002 continuará sin interrupciones ni retrasos en las actividades planificadas de investigación y desarrollo.
Genflow Biosciences (OTCQB:GENFF)는 유럽에서 유일하게 상장된 장수명 관련 기업으로, 벨기에 왈로니아 지역으로부터 이전에 발표한 400만 유로 비희석성 보조금을 확정했습니다. 이 자금은 대사 관련 지방간염(MASH) 치료를 위한 회사의 주요 유전자 치료 후보물질인 GF-1002 개발을 지원할 예정입니다.
이 보조금은 Genflow의 임상 로드맵에 맞춘 3년 개발 프로그램을 포함합니다. 초기 자금 지급은 행정 절차를 기다리고 있으나, 회사는 GF-1002 프로그램이 중단 없이 계획된 연구개발 활동에 지연 없이 계속 진행될 것임을 보장했습니다.
Genflow Biosciences (OTCQB:GENFF), la seule entreprise européenne cotée en bourse spécialisée dans la longévité, a confirmé sa subvention non dilutive de 4 millions d’euros précédemment annoncée par la Région wallonne en Belgique. Ce financement soutiendra le développement de GF-1002, le principal candidat en thérapie génique de la société pour traiter la stéatohépatite métabolique associée (MASH).
La subvention couvre un programme de développement sur trois ans aligné avec la feuille de route clinique de Genflow. Bien que le premier versement soit en attente des procédures administratives, l’entreprise a assuré que le programme GF-1002 se poursuivra sans interruption ni retard dans les activités de recherche et développement prévues.
Genflow Biosciences (OTCQB:GENFF), Europas einzig börsennotiertes Unternehmen im Bereich Langlebigkeit, hat seine zuvor angekündigte nicht verwässernde Förderung in Höhe von 4 Millionen Euro von der Wallonischen Region in Belgien bestätigt. Die Finanzierung wird die Entwicklung von GF-1002 unterstützen, dem führenden Gentherapie-Kandidaten des Unternehmens zur Behandlung der metabolisch assoziierten Steatohepatitis (MASH).
Der Zuschuss deckt ein drei Jahre laufendes Entwicklungsprogramm ab, das mit Genflows klinischem Fahrplan abgestimmt ist. Während die erste Auszahlung noch auf administrative Verfahren wartet, hat das Unternehmen sichergestellt, dass das GF-1002-Programm ohne Unterbrechung oder Verzögerungen bei den geplanten Forschungs- und Entwicklungsaktivitäten fortgesetzt wird.
Positive
- Secured €4 million in non-dilutive funding from Wallonia Region
- Development program for GF-1002 proceeding without delays
- Grant covers three years of development expenses
- 2025 project expenses are eligible for reimbursement
Negative
- Initial grant disbursement still pending administrative procedures
07/17/2025 – 02:00 AM
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Genflow Confirms Approximately €4M Grant Support from Wallonia Region; GF-1002 Program Progressing without Interruption
LONDON, UK – Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF), the only publicly listed longevity company in Europe, announced today that it has secured approximately €4 million in non-dilutive funding from the Wallonia Region of Belgium. This financial injection will fuel the development of GF-1002, the company’s pioneering gene therapy candidate targeting Metabolic Associated Steatohepatitis (MASH), a burgeoning area of unmet medical need. Read the RNS announcing this grant here.
The grant, structured as a three-year development program, strategically aligns with Genflow’s existing clinical roadmap, offering a stable financial runway for its research initiatives. The company highlighted that all project-related expenses incurred in 2025 will be eligible under the grant’s terms. While the initial disbursement is subject to customary administrative procedures, Genflow reassured investors that proactive measures have been implemented to ensure the GF-1002 program remains on schedule, with no anticipated disruptions to ongoing research or development activities.
“We greatly appreciate the continued support from the Wallonia Region,” commented Dr. Eric Leire, CEO of Genflow. “This €4 million in non-dilutive funding is a significant vote of confidence in our science and strategic vision. Our unwavering focus remains on advancing GF-1002 through its next critical development phase, and we’ve taken concrete steps to maintain the program’s momentum uninterrupted.”
Genflow’s commitment to combating the effects of aging and its innovative approach to gene therapy are gaining traction within the investment community. The company’s GF-1002 program exemplifies its efforts to extend healthy lifespans and mitigate the socioeconomic burdens associated with an aging global population. This recent grant from the Wallonia Region positions Genflow to accelerate its research and potentially bring groundbreaking treatments to market, positioning it as a key player in the rapidly evolving longevity sector.
About Genflow Biosciences
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF)(OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow’s lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow’s 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned for 2025, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and X.
DISCLAIMER
The contents of this announcement have been prepared by, and are the sole responsibility of, the Company.
This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company’s or the Directors’ expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “might”, “plan”, “possible”, “potential”, “predict”, “project”, “seek”, “should”, “would” and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company’s actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company’s financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.
Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company’s actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire
FAQ
What is the value of the grant received by Genflow Biosciences (GENFF)?
Genflow Biosciences received approximately €4 million in non-dilutive financial support from the Wallonia Region of Belgium.
What will Genflow Biosciences use the Wallonia Region grant for?
The grant will support the development of GF-1002, Genflow’s lead gene therapy candidate for treating Metabolic Associated Steatohepatitis (MASH).
How long does the Wallonia Region grant support last for GENFF?
The support package spans a three-year development program aligned with Genflow’s existing clinical roadmap.
Is Genflow’s GF-1002 development program experiencing any delays?
No, Genflow has confirmed that the GF-1002 program remains on track with no delays to planned research or development activities.
What makes Genflow Biosciences unique in the European market?
Genflow Biosciences is the only publicly listed longevity company in Europe.
